Non-DMa | DMa |
---|
HbA1C/TyG†| HR (95%CI) | P value | HR (95%CI) | P value |
---|
Low/low (referent) | – | < 0.001 | – | – |
Low/High | 1.91 (1.14–3.20) | 0.014 | 2.10 (1.41–3.12) | < 0.001 |
High/Low | 1.54 (0.90–2.62) | 0.116 | 1.88 (1.26–2.81) | 0.002 |
High/High | 3.22 (2.02–5.16) | < 0.001 | 2.79(1.98–3.93) | < 0.001 |
FPG/TyG†| HR (95%CI) | P value | HR (95%CI) | P value |
Low/low (referent) | – | < 0.001 | – | – |
Low/High | 1.73 (1.23–2.45) | 0.002 | 1.62 (1.01–2.62) | 0.047 |
High/Low | 0.40 (0.06–2.93) | 0.369 | 1.4 3 (0.87–2.34) | 0.161 |
High/High | 3.56 (1.65–7.66) | 0.001 | 1.99 (1.36–2.91) | < 0.001 |
- FPG fasting plasma glucose, HbA1C Glycosylated haemoglobin, TyG triglyceride glucose, HR hazard ratio, CI confidence interval
- †Different cutoff values were used by diabetes status. In non-DM group: Median HbA1C: 5.8%, median FBG: 5.52 mmol/L, median TyG: 8.74; In DM Group: guideling-guide HbA1C: 7.0%, equivalent percentage FPG: 7.11 mmol/L, equivalent percentage TyG:8.95
- aThe log-rank test and backward stepwise selection methods in a Cox proportional hazards regression model was performed; adjusted for age, sex, BMI, current smoker, hypertension, previous MI, previous stroke, previous PCI, previous CABG, non-HDL-C, lipid-lowering and antidiabetes medication use